THE VACCINE AGAINST ROTAVIRUS

International application PCT/RU2014/000318, priority 15.05.2013

Patents for invention

The result of the use of the invention mainly is in increasing the valence of a vaccine against rotavirus: after inoculation with the vaccines claimed in the invention, a person develops immunity to rotaviruses of groups A — C. After vaccination, antibodies to epitopes of VP6, VP8 proteins of different rotaviruses are produced in the body. The ability is formed to produce antibodies in response to ingestion of rotavirus. In the future, if rotavirus A, B or C enters the body, the immune response will be quickly produced, which will be expressed in the fact that it will be possible to avoid infection, or the disease will pass in a mild form.

Along with a preventive, a therapeutic effect is also provided.

The vaccine is safe due to the active substance-recombinant protein, which avoids the risks associated with the introduction of the virus into the body, albeit inactivated.

Assessment of the significance of this development